In IBD animal models, AnxA1 and its N-terminal mimetic peptides are known to attenuate disease progression and promote epithelial repair (Babbin et al., 2008; Ouyang et al., 2012; Zou et al., 2016), and when lacking halts disease remission caused by treatment with infliximab (de Paula-Silva et al., 2016). Here, ANXA1 is linked to inflammatory bowel disease.